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Palavras-chave 
 
Vimentina, filamentos intermédios, crescimento 
cellular, via de sinalização Akt/mTOR, síntese proteica 
 
Resumo 
 
 
A vimentina é uma proteína da classe III dos filamentos 
intermédios que promove processos tais como 
proliferação, migração e invasão celular através da 
interação com diferentes vias de sinalização. No entanto, o 
papel da vimentina no crescimento celular é ainda pouco 
conhecido. Neste estudo, observamos que fibroblastos 
isolados de embriões de ratinhos sem vimentina (Vim -/- 
MEFs) eram mais pequenos que o tipo normal (WT). 
Assim, o objetivo deste estudo era entender de que forma 
a vimentina regula o crescimento celular. Com recurso a 
modelos in vitro, técnicas de microscopia e técnicas 
bioquímicas descobrimos que Vim -/- MEFs tinham menor 
volume e concentração de proteínas quando comparadas 
com WT MEFs. Adicionalmente, a síntese proteica e 
ativação de mTORC1 estavam significativamente 
reduzidas em Vim -/- MEFs. Através de co-
imunoprecipitação, descobrimos que a vimentina interage 
com os complexos mTORC2 e TSC. Assim, postulamos 
que a vimentina regula o crescimento celular por interação 
com proteínas da via de sinalização AKT/mTOR. 
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Abstract 
 
Vimentin is a type III intermediate filament protein that 
takes part in cell proliferation, migration and invasion, by 
acting as a signalling scaffold. The role of vimentin in cell 
growth, however, is poorly understood. We observed that 
vimentin knockout mouse embryonic fibroblasts (Vim -/- 
MEFs) were smaller than the wild type (WT). Therefore, 
this work aimed to understanding how vimentin regulates 
cell growth. Using in vitro models, imaging techniques 
and biochemical approaches, we have found that the 
volume and protein concentration of Vim -/- MEFs is 
lower when compared to WT MEFs. Further, protein 
synthesis and mammalian target of rapamycin complex 1 
(mTORC1) activation was attenuated in Vim -/- MEFs. By 
co-immunoprecipitation we found that vimentin interacts 
with mammalian target of rapamycin complex 2 
(mTORC2) and tuberous sclerosis protein complex (TSC) 
after insulin stimulation. Consequently, we postulate that 
vimentin regulates cell growth by interacting with proteins 
of the AKT/mTOR pathway.  
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1  Introduction  
The cytoskeleton is a fibrous network that maintains the function, shape and motility of 
the cell, supports the organelles, participates actively in the transport of cargo and in various 
signalling pathways. It is comprised of three major classes of proteins:  microtubules, 
microfilaments and intermediate filaments (IFs). Microtubules are the largest type of 
filaments, about 25 nm in diameter. They are polarised structures composed of tubulin that 
provide organisation and organelle positioning. Microfilaments, on the other hand, are made 
of actin and have 6 nm in diameter. Microfilaments are involved in muscle contraction by 
interaction with myosin, but they also play a role in cell division and migration. Finally, 
intermediate filaments are medium sized filaments (10 nm in diameter) composed of more 
than 70 proteins, organised in 6 classes, which are expressed in a tissue specific manner. 
Unlike the other members of the cytoskeleton, IFs are not polarised structures and they have 
numerous roles besides structural support that include migration, proliferation, growth and 
they can act as signalling scaffolds. Therefore, the idea of IFs being static structures has 
changed. Now, it is known that they are essential for many cellular processes, including 
regulation of key signalling pathways. Vimentin, a very versatile type III IF, is essential and 
has a very complex signalling pattern, interacting with specific kinases and regulating their 
function. It is highly expressed in proliferative cells, such as cancer and mesenchymal cells. 
This protein is associated with cancer progression and metastasis, since it can induce 
epithelial to mesenchymal transition (EMT) and promote invasion. Cell growth is essentially 
achieved by synthesis of macromolecules, such as proteins, lipids and nutrients, which is 
regulated by the Akt/mTOR pathway. This dissertation will be focused on understanding the 
mechanisms by which vimentin affects the cell growth. 
 
2 Review of literature 
2.1  Overview of Intermediate Filaments 
It took decades to understand that the cytoskeleton is comprised of three quite distinct 
groups of proteins. A long time was also needed to find out that IFs are actually a big family 
of proteins with different roles and expression patterns (1). The interest began with studies 
of hair fibers, but it was only years after, that IFs were considered a separate class of 
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cytoskeleton proteins, instead of coupled to the other classes (2). Afterwards, many studies 
were published describing the various classes of IFs (3,4). According to their molecular 
features, IFs can be divided in six distinct classes, present in a tissue specific manner: class 
I and II IFs are keratins, found in epithelial cells; class III covers desmin and vimentin, 
existing in muscle and mesenchymal cells, respectively; nestin and neurofilaments, present 
in neurons and stem cells, form class IV of IFs proteins; class V includes lamins, which are 
associated to the nuclear membrane and therefore present in all cell types; finally, class VI 
IFs, phakinin and filensin, are expressed in eye lenses (table 2.1) (5,6). 
 
2.1.1  Structure and assembly of intermediate filaments 
IFs are elastic structures, resistant to stress, allowing them to maintain cell integrity. This 
major class of cytoskeletal proteins is essential for the structure, motility and survival of the 
cell. They are 10-12 nm in diameter and a well conserved structure: a rod alpha-helical 
domain, important for polymerization, flanked by non-helical N and C terminus with high 
degree of variability (1,5). This feature allows specific interactions between IFs and other 
proteins, not only related to mechanical support, but also related to signalling pathways, 
where they mainly act as scaffolds, since they lack enzymatic activity (5).  
The assembly of IFs begins with the interaction between two rod domains, causing 
parallel dimerization of the filaments. Dimers can then associate and form antiparallel 
tetramers, which will then assemble in octamers and form complex structures (figure 2.1; 
(7)). Interestingly, some IFs can polymerise with each other and form homopolymers, while 
others need to assemble with a different type of IF, forming an heteropolymer (8,9), which 
gives even greater versatility to these filaments. In addition, IFs lack polarity and they can 
assemble without the use of energy, which is another characteristic that separates them from 
microfilaments and microtubules. Nevertheless, the spatial assembly of IFs is dependent on 
other members of the cytoskeleton (8,10). (11) 
 
2.1.2  Function and Expression of intermediate filaments 
In the early times of IFs research, the major function of IFs was considered to be structural 
support, but now it is known that they have a wide list of functions that also include organelle 
positioning, roles in migration, adhesion, inflammatory responses and cell stress (reviewed 
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in (12)). Studies on mice with mutations in genes coding for IFs proteins have shown major 
signalling problems (5), suggesting that IFs play a role in signalling as well. 
The reason for the versatility and the wide range of unique characteristics of IFs is mainly 
because of their peculiar expression patterns. IFs are expressed in a tissue specific manner 
but their expression pattern is also dependent on development (13). For example, vimentin 
is expressed in cells of mesenchymal origin, while keratins are present in epithelial cells. 
Nestin is expressed only during development in the nervous system, kidney and muscle. 
Then, with differentiation, it is eventually replaced by other classes of IFs (14). Moreover, 
the extracellular matrix (ECM) can also play a role in the expression of these proteins, 
because differential IFs expression can be seen in the same cell type in different ECM 
environments, enhancing the role of the surrounding environment in these cases (15). 
 
2.1.3  Regulation by post-translational modifications 
While microfilaments and microtubules are mostly regulated by their associated proteins, 
IF regulation occurs by post-translational modifications (PTMs) such as phosphorylation, 
glycosylation and sumoylation, among others, that affect the function and dynamics of the 
network (16,17). Sumoylation, addition of a small protein called SUMO to lysine residues, 
is considered to be a conservative modification on IFs, essential for their assembly and 
solubility, which are key properties of these proteins (18). Glycosylation, on the other hand, 
is thought to be regulating IF phosphorylation, as it occurs close to the phosphorylation sites  
Figure 2.1 Assembly of intermediate filaments. Interaction between two rod domains causes parallel 
dimerization of the filaments. Dimers can then associate and form antiparallel tetramers, which will then 
assemble in protofilaments and further to a complete filament (11). 
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of the proteins (19). Phosphorylation is the most relevant modification in IFs and it occurs 
in the head or tail domains of the proteins, at serine, threonine and tyrosine residues. 
Therefore, IFs are the target of a wide range of protein kinases and protein phosphatases, 
enhancing the diversity and versatility of these proteins as well. The most classical examples 
of kinases that phosphorylate IFs are protein kinase C (PKC) for lamins and stress-activated 
proteins kinases for keratins. Rho kinase is also known to phosphorylate many IFs and Cdk5, 
during development, phosphorylates nestin (reviewed in (6)). This whole picture can get 
even more complex because many PTMs can be present at the same time, crosstalking to 
regulate the function of IFs  (18). Studying the role of IFs in cells is a challenging task, and 
there still are lots of questions regarding this subject. Nevertheless, since signalling pathway 
malfunction is the main reason for the onset and progression of certain diseases, and 
provided that IFs interact with a wide range of signalling molecules, it is imperative to 
understand the interactions between these proteins and cell signalling. 
 
2.1.4  Intermediate filaments and disease 
IFs have been shown to be related to disease already in the early days of research, but 
nowadays, a wide range of diseases are known to be associated with IFs (table 2.1.). These 
conditions arise from problems in the assembly, organisation and regulation of IFs, which 
lead to signalling abnormalities (20). Keratins, for example, are associated with many skin 
and liver diseases (reviewed in (21)). Keratins are perhaps the most studied IFs in terms of 
diseases, since mutations in keratins are directly associated with various pathological 
conditions. Vimentin and type VI IFs, on the other hand, are known to be linked with cataract 
Intermediate 
Filament 
Protein Tissue distribution 
Examples of related 
diseases 
Type I Keratins 9-20 Epithelial cells Epidermolysis bullosa 
simplex, liver diseases Type II Keratins 1-8 Epithelial cells 
Type III 
Vimentin Mesenchymal cells 
Muscle cells 
Cataract 
Desmin Myopathy 
Type IV 
Nestin 
Myoblasts 
Neuroepithelial stem cells 
Not reported 
Neurofilaments CNS neurons Neurodegenerative diseases 
Type V Lamins Widely distributed Laminopathies 
Type VI 
Filensin 
Eye lenses Cataracts 
Phakinin 
Table 2.1 Tissue distribution of the various classes of intermediate filaments proteins. Adapted from 
Pallari and Eriksson, 2006 (5). 
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development, even though vimentin can be indirectly related to many disorders (22,23). 
Further, studies on nestin showed that it is overexpressed in Alzheimer’s disease (24). IFs 
with obvious relations with diseases, such as keratins, are extensively studied, therefore the 
knowledge on these is quite broad. However, research on IFs related to diseases indirectly, 
such as vimentin, is very poor still, and more studies are needed to understand their functions. 
 
2.2  Vimentin as a scaffold protein 
2.2.1  Structure and function 
Vimentin is a type III IF with 466 amino acids and a very well conserved structure. It 
possesses four alpha-helixes in total, flanked by a N (head) and a C (tail) non-alpha-helix 
terminus, that associate in parallel forming homo and heterodimers (17). The heads are 
presented in a symmetric way and have numerous phosphorylation sites, allowing vimentin 
to be regulated by PTMs (16,17). Vimentin is expressed in highly proliferative cells, such as 
cancer and mesenchymal cells, including fibroblasts, endothelial cells lining blood vessels, 
renal tubular cells, macrophages, neutrophils and leukocytes (25). 
As an IF protein, one of the functions of vimentin is structural support, which is supported 
by mice studies showing that lack of this protein leads to defects in the morphology of glial 
cells (26). Nevertheless, vimentin can also regulate the recycling mechanisms of the cell, 
cell adhesion, cell division, cell death, leukocyte transmigration, inflammation, participate 
in organelle trafficking and positioning, interacting with microtubules, and play a role in 
lipid homeostasis (27–30). Vimentin was shown to form a cage around lipid droplets and 
proven to be a facilitator for adipogenesis (27). Studies on vimentin knockout fibroblasts 
showed impaired migration and motility which resulted in defects in wound healing (31,32). 
Interestingly, Vim -/- mice were seen to possess a normal phenotype, showing that vimentin 
is not a critical protein for survival (33). However, these mice showed wound healing 
defects, reduced blood flow during vessel dilation, decreased renal mass and tended to perish 
from renal failure (30,31,34). These observations indicate that vimentin is essential for 
wound healing mechanisms and also modulation of the responses to blood flow in arteries. 
Other studies have shown that vimentin is a marker of epithelial to mesenchymal transition 
(EMT), a cellular reprogramming process in which epithelial cells acquire mesenchymal 
phenotype, altering their shape and motility. These alterations are associated with the 
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expression of vimentin, which is normally mainly expressed in mesenchymal cells (35–37). 
Since EMT is a crucial event in wound healing processes, these observations strongly 
support the previous Vim -/- mice studies (31). Increased expression of vimentin was also 
observed in many tumour cell lines and it was related to increased motility and metastasis 
(38–40), linking EMT to cancer. Furthermore, the hypoxia initiation factor (HIF-1), a 
regulator of the cell response to hypoxia, was demonstrated to regulate vimentin expression 
(41). Since hypoxia can be a driver of metastasis, HIF-1 can promote EMT by regulating 
vimentin’s expression. Further, a study reported that vimentin could interact with p53, a 
known tumour suppressor (42). This study showed that vimentin was capturing p53 in 
response to survival signals and releasing it in the presence of death signals, thereby 
enhancing the role of vimentin in cell death and survival (42). Interestingly, vimentin was 
also demonstrated to be a possible transcription regulator of p53 (42). Studies of the 
molecular mechanisms underlying all these functions have revealed that vimentin plays a 
role in many signalling pathways related to cell adhesion, migration, proliferation and 
survival (43). 
 
2.2.2  Regulation by Post-translational modifications 
The extensive range of roles of vimentin in the cell is mainly achieved by its regulation 
by PTMs. PTMs allow interactions with a wide number of proteins and consequent 
participation in signalling cues. A study showed that vimentin can be sumoylated, but the 
significance of this modification is still poorly understood (44). Glycosylation is known to 
widely occur on the same residues as phosphorylation, working like a competition 
mechanism. This PTM is thought to have complementary roles with phosphorylation, 
regulating the function of vimentin itself  (45,46). Phosphorylation, made by kinases on 
serine, tyrosine and threonine residues, is the most relevant PTM occurring in vimentin, 
since it regulates its association with other proteins. More than 20 phosphorylation sites have 
been identified at the N-terminus of vimentin, most of them on serines. The most commonly 
phosphorylated serine is S38, which is the target of several kinases. In order to reverse 
phosphorylation and keep homeostasis, vimentin interacts with protein phosphatases that 
remove these PTMs (17). 
If one thinks about the cell processes in which vimentin is involved – cell migration, 
growth, proliferation, organelle trafficking, scaffolding – phosphorylation can be considered 
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the main driver of all these. In vivo phosphorylation of vimentin by protein kinase A (PKA) 
on S38 and S72 phosphosites has resulted in assembly of vimentin filaments in BHK-21 
cells (17). Furthermore, multiple phosphorylation by p21 was also seen, regulating structural 
reorganization, as well as phosphorylation by Aurora B, causing segregation of the filaments 
during cytokinesis (47). On the other hand, vimentin interaction with phosphorylated 
extracellular signal-regulated kinase (Erk), was shown to prevent it from being degraded 
therefore keeping it functional in promoting cell proliferation (48). RhoA-binding kinase 
(ROCK) was proven to be a very efficient vimentin kinase causing the collapse of vimentin 
network (49). Vimentin association with protein phosphatase 2A (PP2A) prevented  
phosphorylation of vimentin in vitro (50). Moreover, phosphorylation of vimentin on S38 
by Akt makes vimentin filaments interact with each other, which protects vimentin from 
caspase-induced proteolysis, enhancing cell motility and promoting tumour metastasis (51). 
Vimentin interaction with Scrib, a protein implicated in cell migration, was demonstrated to 
drive cell migration and increase the invasive capacity (52). PKC was shown to promote 
interaction between vimentin and 14-3-3 (53). In addition, vimentin was reported to interact 
with 14-3-3 in different scenarios, regulating signalling pathways related to autophagy 
inhibition and tumorigenesis. One study showed that vimentin is limiting 14-3-3, instead of 
14-3-3 preventing vimentin binding to other proteins (54). Thus, vimentin could be acting 
as a modulator of the signalling pathways requiring 14-3-3, such as the Akt/mTOR pathway 
(55). Even though vimentin can interact with many protein kinases, it does not necessarily 
mean that it is phosphorylated by them. Vimentin can interact with PKC on membrane 
vesicles but no phosphorylation occurs (56). Moreover, vimentin can be associated with Raf-
1 kinase and it is not phosphorylated by it (57). Taken together, these observations suggest 
that vimentin is an essential protein in many distinct signalling pathways, mainly related to 
cell growth, proliferation and motility and that phosphorylation is essential for these 
functions to be conducted. Nevertheless, phosphorylation is not mandatory for vimentin to 
interact with protein kinases. 
 
2.2.3  Vimentin and disease 
Mutations that cause a single amino acid change can be the reason for the arise of diseases. 
One study showed that a vimentin mutation that caused a change in one amino acid is 
involved in rheumatoid arthritis (58). In addition, cataract formation is also associated with 
8 
 
this sort of mutations, even though vimentin is involved in cataracts in many different ways 
(59). Vimentin can also be related to other disorders in a more indirect way, such as 
neuropathies and cancer. Vimentin aggregation is seen in a neuropathy caused by mutations 
in a E3 ligase adaptor protein (60–62). Hence, here, the problem is not vimentin itself, but a 
mutated protein that affects the function of vimentin, although the mechanism is still poorly 
understood.  As mentioned before, studies on Vim -/- mice showed that vimentin is not 
essential for normal development and survival but these mice were demonstrated to have 
severe wound healing defects (30,31). Even though wound healing defects might not be 
pathogenic, the mechanisms of wound healing and the mechanisms of cancer invasion can 
be linked by EMT (35). Therefore, since vimentin plays a role in key processes of the cell, 
further studies on the molecular mechanisms by which vimentin regulates cell functions are 
needed. 
 
2.3. Cell growth regulation 
To divide and proliferate, the cell firstly needs to grow. This is mainly achieved by 
synthesis of macromolecules, such as proteins and lipids, upon stimulation. The regulation 
of the size of a cell is essential to keep proper development and function in a multicellular 
organism context, where growth and division are coordinated in proliferating cells, so that a 
doubling in mass occurs for each division (63). Nevertheless, cell cycle is independent from 
cell growth, and cells can grow without dividing (64–66).  
There are various pathways involved in the regulation of cell size, and these can interact 
with each other, acting in agreement with the necessities of the multicellular organisms. This 
regulation, unlike unicellular organisms, in which growth depends mainly on the amount of 
nutrients available, is achieved by a balance between synthesis and degradation of 
macromolecules, in response to different stimuli, integrating nutrients and growth factors 
(63,67). Mitogens can activate the transcription factor Myc that will increase ribosomal RNA 
levels and protein synthesis, leading to an increase of the cell size and cell cycle progression 
(68). Cells overexpressing Myc were seen to be much larger than the wild type ones. On the 
other hand, studies with Drosophila have shown that partial loss of Myc resulted in miniature 
flies (69).  
A second way of cell size regulation is the Hippo pathway. It comprises a group of tumour 
suppressors that can control cell number by promoting apoptosis and inhibiting proliferation 
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(70). Mutations in any of the implicated genes of the Hippo pathway showed exaggerated 
cell growth. Furthermore, the heads of adult flies with Hippo mutations were larger when 
compared to the wild type ones (71–73). Interestingly, studies have shown the existence of 
a feedback loop where Myc can regulate cell growth by affecting the activity of the Hippo 
pathway (68). Moreover, it was demonstrated that the expression of Myc can be actually 
controlled by yes-associated protein (Yap), a transcription factor that is part of the Hippo 
pathway (68). Both pathways can also interact with the one that might be the major regulator 
of cell size in most types of cells - the Akt/mTOR pathway, a signalling cascade activated 
by insulin and other growth factors that ultimately leads to protein synthesis. 
 
2.3.1.  The Akt/mTOR pathway 
Insulin, along with other growths factors, can trigger the insulin receptor and the insulin 
like growth factor (IGF) receptor and regulate cell growth by controlling the Akt-mTOR 
pathway (figure 2.2). Activation of the receptor causes activation of pyruvate dehydrogenase 
kinase 1 (PDK-1) by phosphoinositide 3 kinase (PI3K), which in turn activates Akt, also 
called protein kinase B (PKB). Akt will then phosphorylate TSC, causing disassembly of the 
TSC inhibitory complex from mTORC1. mTOR is a serine threonine protein kinase crucial 
for several survival cues in the cell, and it can form two different complexes: mTORC1, 
referred above, which is mainly characterised by regulatory associated protein of target of 
rapamycin (RAPTOR), proline-rich Akt substrate 40 (PRAS40) and the common subunits; 
and mTORC2, comprised by rapamycin insensitive companion of target of rapamycin 
(RICTOR) and the common subunits. TSC complex functions as a GTPase activating protein 
(GAP) for Ras homolog enriched in brain (Rheb), which, when bound to guanosine 
triphosphate (GTP), interacts with mTORC1 and increases its kinase activity. Thus, removal 
of TSC complex  promotes GTP binding to Rheb, activating mTORC1, which will then 
phosphorylate eukaryotic translation initiation factor 4E binding protein (4E-BP1) and S6 
kinases (ribosomal proteins; reviewed in (74)). While 4E-BP1 prevents translation, 
phosphorylated 4E-BP1 causes release of eIF4E, leading to protein synthesis (75,76). 
Furthermore, mTORC2 can  be regulated by PI3K and fully activate Akt by phosphorylation 
of Akt on Ser473 (77). The Akt/mTOR pathway is functioning in the presence of nutrients, 
and, during fasting, the pathway is supressed. This pathway ultimately leads to the regulation 
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of protein synthesis (figure 2.2) (74), as well as nutrient uptake and lipid synthesis, all of 
which drive cell growth. 
 
2.3.1.1. Insulin receptor signalling 
The Akt/mTOR pathway is triggered by insulin and IGFs by binding to insulin and IGF 
receptors, which are highly homologous receptor tyrosine kinases (RTK). These are 
composed by two alpha extracellular subunits and two beta transmembranar subunits, both 
generated from the same precursor that suffers alternative splicing (78). The insulin receptor 
family includes various forms of the receptors, which can have different outcomes and are 
tissue specific (79). These receptors are activated mostly by insulin and IGF-1 and they can 
initiate a cascade of phosphorylation that controls many aspects of the metabolism. Although 
insulin and IGF-1 prefer to bind to their own receptor, they can also bind to each other’s 
receptor with lower affinity (80). Studies on knockout mice for different insulin receptor 
ligands showed distinct phenotypes and abnormalities between them (81,82), suggesting that 
distinct processes can be affected depending on which ligand is binding, even though they 
possess similar motifs. The main pathway activated by insulin receptors is the Akt/mTOR, 
Figure 2.2 Simplified model of the Akt/mTOR pathway. Activation of the receptor causes phosphorylation 
of PDK-1 by PI3K, which in turn activates Akt. Akt will then phosphorylate TSC, causing disassembly of the 
TSC inhibitory complex from mTORC1. This promotes GTP binding to Rheb, thus activating mTORC1, which 
will then phosphorylate 4E-BP1 and S6 kinases. This pathway ultimately leads to the regulation of protein 
synthesis and cell growth by controlling gene expression.  
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via PI3K-PDK-1, as referred above, but PKC is also activated by these receptors and it has 
a very important role on glucose transport and regulation of lipid synthesis (83). In addition, 
the mitogen activated protein kinase (MAPK) pathway can also be triggered by insulin 
receptors and affect cell proliferation by controlling gene expression (84,85). Neither MAPK 
nor PKC pathways depend on Akt/mTOR function. Akt activation, besides triggering the 
whole Akt/mTOR pathway referred above, also leads to other secondary pathways that 
complement each other. For example, Akt can phosphorylate forkhead box O (Foxo), 
regulating lipid synthesis and gluconeogenesis (86). Akt can also phosphorylate murine 
double minute 2 (mdm2), the inhibitor of p53, inhibiting apoptosis (87). Still related to cell 
survival, Akt phosphorylates caspase 9 and  Bcl-2-associated death promoter (Bad), 
inhibiting apoptosis through a different pathway (88–90). In addition, Akt can trigger the 
nuclear factor kB (NF-kB) signalling pathway by phosphorylating the inhibitor of kB (IkB) 
kinase (91). Further, Akt can be involved in vasodilation, glucose uptake, fatty acid 
oxidation, autophagy control, among other cell functions, by phosphorylating additional 
proteins and starting different cascades (77,92,93). One study showed that Akt could inhibit 
beclin-1 and inhibit autophagy, enhancing tumorigenesis. In fact, Akt was observed to inhibit 
beclin-1, which was interacting with both 14-3-3 and vimentin, suggesting that a protein 
complex composed by these four proteins can be promoting tumorigenesis (94).  
Uncontrolled activity of insulin receptor signalling pathways can lead to major 
unbalances in metabolism and tumorigenesis. Various protein tyrosine phosphatases 
attenuate the signal and reduce the activity of the receptor, keeping homeostasis (95). It is 
necessary to consider that all these pathways can crosstalk, and the information must be 
combined to keep homeostasis. 
 
2.3.1.2.  Crosstalk to regulate cell growth 
As stated in the previous sections, insulin receptor signalling triggers a significant part of 
the key processes in the cell, and most of them involve Akt. Interestingly, all outcomes from 
insulin receptor signalling promote cell survival, growth and proliferation. Activation of the 
MAPK pathway by growth factors leads to activation of Myc, a very important transcription 
factor in the cell (84). Some of the targets of Myc are translation initiation factors, which are 
downstream mTORC1 (96,97). Even further, Myc can affect directly the TSC complex, a 
key complex of the Akt/mTOR pathway, by binding to the promoter of TSC (98). These 
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findings point to a crosstalk between distinct pathways that can be activated by the same 
family of receptors and act in agreement to control cell growth and proliferation through a 
complex network of feedbacks (figure 2.3). 
The Hippo pathway can coordinate cell growth and affect cell number and it was 
demonstrated to be interacting with these pathways, affecting essential proteins upstream of 
Akt. It was reported that the Hippo pathway is able to regulate IGF-1, which is an activator 
of insulin receptor signalling (99). On the other hand, members of the Hippo pathway were 
shown to inhibit phosphatase and tensin homolog (PTEN), an inhibitor of PI3K. This way, 
the loss of members of the Hippo pathway was shown to cause activation of mTORC1, 
leading to increased cell growth (100–102). Furthermore, since PI3K is directly activated by 
the insulin receptor, the whole downstream signalling is affected by upregulation of PI3K. 
These findings point for a crosstalk between the different pathways controlling cell size and 
provide evidence that the Hippo pathway can control the outcomes of insulin receptor 
signalling. 
2.3.1.3. Mutations in the Insulin/Akt/mTOR pathway lead to size defects 
To understand the outcomes of the Akt/mTOR pathway, several studies have been 
conducted with knockout animal models. Studies in Drosophila have shown that deletion of 
p70S6K reduces cell and body size (103). Similar results were found with mice lacking 
PDK-1, that the mice themselves were smaller in body size (104).  
In addition, isolated mouse embryonic fibroblasts (MEF) from PDK-1 null mice were 
about 30% smaller than the wild type ones (104). In agreement with the other results, 
depletion of PI3K in cells caused impaired growth,  whereas overexpression of this protein 
resulted in abnormally big cells (105,106). Even further, knock-out of insulin receptor 
ligands in mice resulted in growth retardation (revised in (107)). A study made with 
Drosophila, to evaluate the effect of the loss of dTOR, the homolog of mTOR in the flies, 
showed that the mutant cells were dramatically reduced in size, enhancing the role of this 
protein in cell size control (108). All these studies support the idea that the Akt/mTOR 
pathway is a key pathway controlling cell size and growth.  
 
2.3.1.3.1. Pathological conditions associated 
The overall mechanisms regulated by insulin receptor signalling, are related to cell 
survival and proliferation and the Akt/mTOR pathway can participate in controlling all these 
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processes. The knockout animal models studies referred above showed, consistently, the 
defects on growth. On the other hand, studies have shown that mutations that increase the 
activity of  the PI3K/Akt/mTOR signalling pathway reduce autophagy (revised in (85)). As 
examples, common cancer mutations, such as on the tumour suppressor p53, are able to 
promote constitutive activation of mTORC1 (109), explaining the increased growth and 
reduced organelle recycling in cancer. Another typical cancer mutation is the loss of the 
tumour suppressor PTEN, which results in increased activity of the Akt/mTOR pathway, 
because PI3K becomes continuously active (110). Also, other diseases can be associated 
with the Akt/mTOR pathway. A rare genetic disease caused by mutations in TSC results in 
the development of non-malignant tumours in many organs (111). Furthermore, given the 
relationship between this pathway and lipid synthesis, it can also be linked to metabolic 
diseases such as obesity, fatty liver diseases, insulin resistance and type II diabetes (revised 
in (112)). Therefore, an extensive range of disorders can either arise from, or be affected by 
the Akt/mTOR pathway. 
 
 
Figure 2.3  Crosstalk between Hippo, MAPK and Akt/mTOR pathways. The Hippo pathway can 
inhibit PTEN, keeping PI3K active. The myc pathway can regulate the other two pathways by gene 
expression regulation. 
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3  Aims and outline 
Vimentin, a type II IF, was shown to be involved in various signalling pathways related 
to cell migration and proliferation. Although the role of vimentin in cell proliferation and 
migration are widely studied, the mechanisms by which vimentin regulated cell growth 
remain unknown. The regulation of cell growth is done by a balance between synthesis and 
degradation of macromolecules, such as proteins. We hypothesised that vimentin regulates 
cell growth. Consequently, this dissertation has as main aim to understand if vimentin 
regulates cell growth and as second aim unravel the underlying molecular mechanism. To 
do this, a series of in vitro experiments, namely cell volume, protein amount and protein 
synthesis were performed with mouse embryonic fibroblasts, to discuss whether vimentin is 
responsible for the size differences. Vimentin rescue experiments were also conducted to see 
if the normal phenotype could be restored. mTOR activation was then studied to understand 
the differences in the Akt/mTOR pathway between WT and Vim -/- MEFs, since this is the 
pathway responsible for protein synthesis. In parallel, a series of mouse experiments were 
made to investigate the influence of vimentin on body size. Using co-immunoprecipitation 
with human dermal fibroblasts, the role of vimentin in cell growth was studied by checking 
whether it interacted with proteins of the cell growth pathway. Finally, by means of mass 
spectrometry, the candidates for this phosphorylation dependent interaction were studied. 
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4  Materials and Methods 
4.1  Animal Experiments 
WT and Vim -/- mice generated from the heterozygous 129/SvJ x C57BL/6 were used in 
all experiments.  
4.1.1  Genotyping 
Ear samples taken from both WT and Vim -/- mice were heated at 55 ºC with proteinase 
K (0.2 mg/ml) and 400 µl of lysis buffer (10 mM Tris pH 8.0, 200 mM NaCl, 5 mM EDTA 
and 0.2 % SDS). When the ear pieces were completely dissolved, the samples were 
centrifuged for 3 minutes at 5000 rpm and the supernatant was put into new tubes. The tubes 
were incubated at room temperature for 5 minutes with 500 µl of isopropanol, followed by 
centrifugation. The supernatants were, then, discarded and 1 ml of 70 % ethanol was added, 
followed by vortexing and 3 minutes of incubation at room temperature. The samples were 
centrifuged; the supernatant was discarded and they were left to dry. Then, 100 µl of sterile 
water was added to each tube and the polymerase chain reaction (PCR) was prepared with 2 
µl of sample, 0.2 µM of each primer (forward primer for WT sequence: 5’ TGT CCT CGT 
CCT CCT ACC GC 3’; forward primer for Vim -/- sequence: 5’ AGC TGC TCG AGC TCA 
GCC AGC 3’; common reverse primer: 5’ CTG TTC GCC AGG CTC AAG GC 3’) and 
21.5 µl of Taq Ready Mix (GE Healthcare, UK). The PCR conditions are described in table 
4.1. Next, the samples were resolved in a 2 % agarose gel. 
 
Step Temperature (ºC) Time Cycles 
Denaturation 95 3 minutes 1 
Denaturation 94 1 minute 
35 Annealing 65 20 seconds 
Extension 72 30 seconds 
Final extension 75 5 minutes 1 
Hold 4 infinite - 
 
4.1.2  Body weight 
To evaluate body weight, WT and Vim -/- male mice with of three and six months old 
were weighted. 
Table 4.1 PCR conditions used for genotyping. 
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4.1.3 Organ weight and Size 
To evaluate organ size, WT and Vim -/- male mice with the same age were sacrificed by 
cervical dislocation. The organs of interest, kidney and heart, were collected, photographed 
and weighted. The organs were fixed with 3 % paraformaldehyde (PFA) for further 
experiments. 
4.1.4  Tissue sectioning and staining 
The organs of interest, liver, kidney, intestine and adipocyte, of the sacrificed mice were 
fixed with PFA and embedded paraffin. The sectioning and haematoxylin-eosin staining was 
carried out by Loinais-Suomen pathology laboratory. The sections were imaged using 
Panoramic Slide Scanner (3DHISTECH, Hungary) and Image J was used for analysis. 
 
4.2  Cell lines and cell culture 
All the cell lines were cultured in Dulbecco’s modified medium (DMEM) supplemented 
with 10 % fetal calf serum (FCS), 2 mM of L-glutamine, 100 U/ml of penicillin, 100 µg/ml 
of streptomycin at 37 ºC in a 5% CO2 incubator and passaged when they were about 80 % 
confluent. 
Immortalized mouse embryonic fibroblasts (MEF), wild type and Vim -/- were used (113). 
Human dermal fibroblasts (HDF) were bought from American Type Culture Collection 
(ATCC). 
4.1.1  Transfections 
Vim -/- MEFs were seeded in 6-well plates on the day prior transfection. The cells were 
transfected with 10 µg of pCMV script-vimentin and untransfected cells were used as a 
control. The transfection method that was used was XfectTM (Clontech Laboratories, USA), 
according to the instructions of the manufacturer. This chemical method uses a 
biodegradable polymer has a transfection agent and it has very low cytotoxicity and it is very 
efficient. These transfection experiments aimed to understand whether the WT phenotype 
and signalling could be rescued by inserting vimentin plasmid into Vim -/- MEFs. Therefore, 
these transfected cells were used for volume analysis. 
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4.1.2  Treatments 
Human dermal fibroblasts were starved with serum free medium (SFM) on the day prior 
to co-immunoprecipitation. The next day they were treated either with 5 % FCS or 100 nM 
of insulin for 10 minutes and cells with no treatment were used as control. An additional 10 
minute treatment with 10 nM calyculin A, a phosphatase inhibitor, was made for the co-IP 
of TSC2 as a positive control and, once again, cells without this treatment were used as 
control. These treatments allowed stimulation of the insulin-Akt-mTOR pathway so that the 
signalling could be evaluated. The same treatment was applied to MEFs before evaluating 
mTORC1 activation by SDS-PAGE and Western Blotting, but 10 nM of insulin was used 
instead. A 1 nM thymidine treatment of 24 hours was made to the cells before performing 
cell volume assays to ensure that the cells were all at the same cell cycle stage (G1/S phase) 
and exclude volume differences related to cell cycle. 
 
4.2  Assays 
4.2.1  Cell volume assay 
In order to evaluate the cell volume, WT and Vim -/- MEFs were grown in 6-well plates 
overnight. The samples were trypsinised and fixed with 3 % PFA for 20 minutes in the dark 
and then stained with 2 µM of CellTrackerTM fluorescent probes (ThermoFisher Scientific, 
USA), which pass through the cell membrane freely, become impermeant and are well 
retained by the cell. 
Leica TCS SP5 Matrix confocal microscope was used to image the samples and to take a 
z-stack to be able to calculate the cell volume. The results were analysed using Imaris® 
software 8.1 (BITPLANE, Switzerland). Three biological replicates were performed for this 
experiment. 
4.2.2  Total protein concentration assay  
In order to evaluate the protein concentration, WT and Vim -/- MEFs were seeded in 6-
well plates and incubated overnight. On the next day, the cells were trypsinised and 3,0x105 
were lysed for 1 hour in a buffer containing 150 mM NaCl, 1 % Triton X-100, 0.2 % SDS, 
50 mM Tris pH 8.0 and 0.5 % of sodium deoxycholate at 4 ºC. Then a BCA assay 
(ThermoFisher Scientific, USA) was performed according to manufacturer’s instructions. 
This colorimetric assay is based on the reduction of copper by protein in an alkyne medium 
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(biuret reaction), forming a purple complex, which absorbance can be measured at 562 nm. 
Three biological replicates were made for this experiment. 
4.2.3  Protein synthesis assay 
In order to evaluate protein synthesis rate, WT and Vim -/- MEFs were seeded in 96-well 
plates and starved overnight. The assay was carried out using the Click-iT® HPG Alexa 
Fluor® Protein Synthesis Assay Kits (ThermoFisher Scientific, USA), which uses an 
analogue of methionine containing an alkyne that is incorporated during protein synthesis 
and can be detected by a chemoselective reaction between the alkyne and an azide present 
in the fluorescent dye (Alexa Fluor 488) to quantify protein synthesis. The medium was 
changed to methionine free with 50 µM of the methionine analogue. The cells were treated 
with 100 nM of insulin for 30 minutes and cells with no treatment were used as control. This 
was followed by PBS wash, 20 minutes of 3 % PFA fixation, 5 minutes of PBS 0,3 % Triton 
X permeabilization and 1 hour of blocking at room temperature with PBS 0,3 % Tween 3 % 
BSA. Then, the Click-it reaction was prepared according to the instructions and added to the 
cells for 30 minutes in dark. The cells were washed and kept in PBS. The imaging was 
performed with Cell-IQ (CM Technologies Oy, Finland) using the green channel and 10 X 
plan, 1392x1040 pixels. The analysis of the images was carried out with the Cell-IQ 
Analyser software by measuring the intensity. Three biological replicates were performed. 
 
4.3  Co-Immunoprecipitation  
Three groups of starved HDF cells were used for this experiment, in which cells were 
either treated with 5 % FCS or 100 nM of insulin for 10 minutes, and cells with no treatment 
were used as control. The cells were washed with PBS and lysed with a lysis buffer 
containing 0.3 % CHAPS, 40 mM HEPES, 120 mM NaCl, 1 mM EDTA, phosphatase 
inhibitor and proteinase inhibitor and then collected to tubes. The samples were shaken for 
1 hour at 4 ºC, while the magnetic beads were being washed. The samples were centrifuged, 
the supernatant was collected and the protein concentration was measured using a BCA 
assay. New tubes with 500 µg of protein were incubated with 0.20 µg of magnetic beads at 
4 ºC for 1 hour. The samples were placed on the magnet; the supernatant was collected to 
new tubes and 1 ng of antibody (table 4.2) was added for incubation during 1 hour at 4 ºC. 
IgG was used as a negative control. Then, 0.25 µg of magnetic beads was added to each tube, 
19 
 
followed by 1 hour incubation at 4 ºC. The samples were finally washed with lysis buffer 
and boiled for 10 to 15 minutes at 98ºC with 1x laemmli buffer (62.5 mM Tris-HCl pH 6.8, 
1 % SDS, 10 % glycerol, 0.005 % bromophenol blue and 1 % beta-mercaptoethanol).  
 
4.4  Immunostaining  
4.4.1  Volume analysis 
The MEF WT and Vim -/- cells and rescued cells were trypsinised and centrifuged. The 
samples were fixed with 3 % PFA and incubated for 20 minutes in the dark. After 
centrifugation, the samples were washed three times with PBS and permeabilised for 5 
minutes with PBS 0.3 % tween. The blocking was performed for 1 hour using PBS 0.3 % 
tween 3 % BSA. Vimentin primary antibody (Biolegend, USA) was diluted 1:1000 in PBS 
0.3 % tween 3 % BSA. The samples were incubated with the antibody overnight at 4 ºC. 
After washing the samples three times with PBS 0.3 % tween, they were incubated with the 
secondary antibody (chicken, Invitrogen, UK), diluted 1:500 in PBS 0.3 % tween 3 % BSA, 
for 1 hour at room temperature, in the dark. The samples were then washed once again and 
kept in PBS at 4 °C in the dark for further analysis. 
 
4.5  Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) and Western Blotting 
The samples were prepared by heating for 10-15 minutes at 98 ºC with 1x laemmli buffer, 
and then resolved in a SDS-PAGE gel (6-15 %) with a buffer containing 250 mM glycine, 
25 mM Tris-base and 0.1 % SDS. The gels were run for 30 minutes at 80 V, followed by 90 
minutes at 120 V. The resolved samples were transferred to a nitrocellulose membrane using 
wet transfer, with 400 mA for 1 hour. The buffer used contained 192 mM glycine, 24 mM 
Tris-base and 20 % methanol. Next, the membranes were blocked with 5 % milk in PBS 0.3 
% Tween and then incubated with the desired primary antibody (table 4.2), diluted 1:1000 
in 3 % BSA in PBS 0.3 % Tween, overnight at 4 ºC. On the next day, the membranes were 
washed with PBS 0.3 % Tween and incubated with the appropriate secondary antibody (table 
3.3.), diluted 1:10000 with 5 % milk in PBS 0.3 % Tween, for 1 hour at room temperature. 
20 
 
The membranes were washed once again and exposed with enhanced chemiluminescence 
(ECL) western blotting substrate (ThermoFisher Scientific, USA).  
4.6  Microscopy 
4.6.1  Cell Volume 
The ©Leica TCS SP5 Matrix confocal microscope was used to measure 3D cell volume 
with 20X plan, 1024x1024 pixels, with both red and green channels. A z-stack was taken to 
all samples for further volume analysis. 
4.6.2  Protein synthesis 
The imaging was performed with Cell-IQ (CM Technologies Oy, Finland) using the green 
channel and 10 X plan, 1392x1040 pixels. The analysis of the images was carried out with 
the Cell-IQ Analyser software by measuring the intensity of the fluorescence. 
 
Primary Antibody Used for Company Secondary Antibody Company 
S6 WB Cell Signalling Technology, USA Rabbit Promega, USA 
p70S6K WB Cell Signalling Technology, USA Rabbit Promega, USA 
p-S6 WB Cell Signalling Technology, USA Rabbit Promega, USA 
p-p70S6K WB Cell Signalling Technology, USA Rabbit Promega, USA 
Insulin Receptor WB Cell Signalling Technology, USA Rabbit Promega, USA 
HSC70 WB Enzolifesciences, USA Rat GE Healthcare, UK 
RICTOR WB Bethyl, USA Rabbit Promega, USA 
RICTOR IP Millipore, UK Mouse Proemga, USA 
TSC2 WB, IP Cell Signalling Technology, USA Rabbit Promega, USA 
Vimentin WB Cell Signalling Technology, USA Rabbit Promega, USA 
Vimentin 9 WB Sigma-Aldrich, USA Mouse Promega, USA 
IgG IP Millipore, UK Mouse Promega, USA 
IgG IP Cell Signalling Technology, USA Rabbit Promega, USA 
 
4.7  Mass spectrometry analysis 
The samples used for mass spectrometry were prepared from a co-IP of RICTOR as 
described previously. Then the samples were run in a precast 10 % SDS-PAGE gel (Bio-rad, 
USA) for 1 hour at 200 V, followed by silver staining. To identify the phosphorylation sites, 
we performed in-gel alkylation and digestion with trypsin, C18 reverse phase 
chromatography and LC-MS/MS using a Q Exactive (ThermoFisher Scientific, USA), a ESI-
hybrid-quadrupole-orbitrap. The mobile phase was water 0.1 % formic acid (FA) (v/v) 
(solvent A) or acetonitrile (ACN)/water 80:20 (v/v) 0.1 % FA (v/v) (solvent B) at a flow rate 
Table 4.2 List of primary antibodies and respective secondary antibodies used for WB and Co-IP. 
21 
 
of 300 nl/min. The peptides were separated by gradient elution from 5-43 % solvent B in 18 
minutes, followed by 2 minutes of 43-100 % (v/v) solvent B and 5 minutes of 100 % solvent 
B. Before running the samples, they were dissolved in 0.1 % FA. The scan range was set 
from 300-17500 m/z with HCD (higher energy collisional dissociation) fragmentation and 
up to 10 data-dependent MS/MS spectra were fragmented in each scan with 10 seconds’ 
dynamic exclusion. An inclusion list of theoretical tryptic peptides was made by in-silico 
digestion using Swiss-Prot (Homo Sapiens vimentin) in Skyline (MacCoss Lab Software, 
USA) to increase the probability of identification of the peptides. The analysis of the results 
was made using Proteome Discoverer 2.1 (ThermoFisher Scientific, USA) and the database 
search was made using Mascot 2.5.1 (Matrix Science, USA), using phosphorylation and 
methylation as variable modifications and carbamidomethylation as fixed modification with 
10 ppm of mass tolerance for precursors and 0.2 Da for fragment ions with m/z ≥ +2. It was 
allowed one miss-cleavage and the validation was made using decoy database search with 
target false discovery rates (FDR) of 0.01 (strict) and 0.05 (relaxed); and ptmRS with a 
confidence threshold set to p<0.05. 
4.8  Statistical Analysis 
All the statistical analysis was carried out using the GraphPad Prism 7 (GraphPad 
Software Inc., USA). An unpaired non-parametric student’s t-test was conducted for all the 
data with n ≥ 3 biological replicates. The data is presented in the form of mean ± standard 
error of the mean (SEM). 
4.9  Figure panels and illustrations 
All illustrations were made with Adobe Illustrator and using Servier Medical Art. All 
figure panels were made using CorelDRaw X8 (Corel, Canada).  
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5  Results  
5.1  Loss of vimentin reduces cell size 
Vimentin is an IF protein that plays a role as a scaffold in many cell signalling pathways 
related to proliferation, migration and survival. Initially, MEFs lacking vimentin were 
observed to be smaller in size, when compared to WT MEFs (figure 5.1A). This lead us to 
hypothesise that vimentin plays a role in growth regulation. To test this hypothesis and to 
confirm that the observed difference was not caused by differential cell spreading, we 
quantified the cell volume of wild type (WT) and vimentin knockout (Vim -/-) MEFs. The 
cells were trypsinised, fixed and stained with a dye for the whole cell. Using confocal 
microscopy (figure 5.1B) and imaging tools, the 3D cell volume was measured (figure 5.1C). 
We found that Vim -/- MEFs were 20-25 % smaller than WT MEFs (figure 5.1D). The same 
experiment was conducted using cells treated with thymidine for 24 h, which synchronised 
the cells in G1/early S phase to exclude differences due to cell cycle progression. We 
observed a similar difference in cell volume (figure 5.1E), supporting the previous 
experiment. Then, we wanted to confirm whether vimentin was responsible for this 
phenotype or not, so we transfected Vim -/- MEFs with 10 µg of pcMV-script vimentin and 
we performed the same cell volume experiment. Indeed, an increase in cell volume was 
observed after rescuing the cells (figure 5.1F), suggesting that the lack of vimentin makes 
the cells smaller than WT. However, this experiment lacked an empty vector control and it 
will be performed again. To further confirm these results, we lysed both WT and Vim -/- 
MEFs and we measured protein amount using a BCA assay, since cell volume is directly 
related with the amount of protein in the cells. With this experiment, we observed that protein 
amount in Vim -/- MEFs was significantly lower than in WT MEFs, supporting the previous 
results on cell volume (figure 5.1G). Cell growth is tightly regulated by insulin and other 
growth factors that lead to protein synthesis. Since the protein concentration was lower in 
Vim -/- MEFs, we then performed a protein synthesis assay using a fluorescent marked 
methionine protein synthesis assay kit. The relative level of protein synthesis was 
significantly lower in Vim -/- MEFs, which suggests that the difference seen in the phenotype 
could be due to a malfunction in the protein synthesis pathway, caused by the lack of 
vimentin. Further, insulin stimulation after cell starvation lead to an increase in cell volume 
in WT MEFs but not in Vim -/- MEFs (Mohanasundaram et al. unpublished), suggesting that 
loss of vimentin disrupts insulin dependent signalling in MEFs.  
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Interestingly, studies in mice showed that Vim -/- mice weight 20-25 % less than WT 
mice (figure 5.2A) and fellow lab colleagues demonstrated that the body mass index 
(mass/height2) of Vim -/- mice was significantly lower than WT mice (Mohanasundaram et 
al. unpublished). In addition, kidneys and hearts isolated from Vim -/- mice were not only 
lighter than the WT organs (figure 5.2B) but also smaller (figure 5.3C-D). As a support, we 
sectioned various tissues from the mice. Using haematoxylin-eosin (HE) staining, followed 
by imaging and cell size quantification, we found that adipocytes from Vim -/- mice were 
Figure 5.1 Vim -/- MEFs are smaller than WT. a. Phase contrast representative image of WT and Vim -/- 
MEFs showing that Vim -/-  MEFs are smaller than WT. b. Maximum projection of WT MEFs shown in red 
and Vim -/- MEFs in green after a z-stack taken with a confocal microscope. c. Representative 3D 
reconstruction made with Imaris software (BITPLANE) of a z-stack taken to the MEFs which was used to 
estimate the volume of the cells d. Cell volume of Vim -/- MEFs is lower than WT. e. Cell volume of Vim -/- 
MEFs is lower than WT after a 24 h thymidine treatment. f. Rescued MEFs show an increase in cell volume 
when compared with untransfected Vim -/- MEFs. g. Vim -/- MEFs have lower protein amount. The same 
number of WT and Vim -/- MEFs were lysed for 1 hour at 4ºC and then a BSA assay was conducted. h. 
Fluorescent based protein synthesis assay shows decreased protein synthesis in Vim -/- MEFs upon insulin 
stimulation. The results are presented in the form of mean ± standard deviation of the mean of three biological 
replicates (n=3) and a student t-test was performed. *** p<0.001; *p<0.05. 
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significantly smaller than the WT adipocytes (figure 5.2E-F). Other sections were made for 
kidney, liver and smooth muscle but the size analysis was not successful because these 
Figure 5.2 Vim -/- mice are smaller than WT. a. body weight of a group of WT and Vim -/- male mice of 3 
months old (n=6) and a group of WT and Vim -/- male mice of 6 months old (n=4), showing decreased body 
weight in about 20 % in Vim -/- mice. b. kidney (n=6) and heart (n=3) organ weight of male mice of 4 months 
old, showing decreased organ weight in Vim -/- mice. c. Vim -/- kidneys are smaller than WT. d. Vim -/- hearts 
are smaller than WT.  e. Adipocytes show decreased cell size in Vim -/- mice. f. The area of the adipocytes was 
quantified using ImageJ tools and a student t-test was used to evaluate the significance of the results. Sections 
of WT and Vim -/- (n=4) mice with 3 months old were used. The results are presented in the form of mean ± 
standard deviation of the mean of the biological replicates. *p<0.05; **p<0.01. 
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tissues are very dense, compact and complex. Supporting results were obtained by fellow 
lab colleagues by EcoMRI, which showed that Vim -/- mice are much leaner that WT mice 
(Mohanasundaram et al. unpublished).  
 
5.2 Vimentin regulates cell size through insulin/Akt/mTOR signalling 
The main pathway regulating protein synthesis production is the Akt/mTOR pathway, 
triggered by insulin and other growth factors, by binding to insulin and IGF receptors. 
Therefore, the next step was to evaluate differences in the Akt/mTOR pathway between WT 
and vim –/- MEFs, using biochemical techniques. We starved WT and Vim -/- MEFs 
overnight and stimulated them with insulin or FCS for 10 minutes. Then, we harvested the 
cell lysates with laemlli buffer and boiled the samples for 15 minutes at 98 ºC. We performed 
SDS- PAGE and western blotting and we found that the phosphorylation of p70S6K on T389 
and S6 on S234/236 were attenuated in Vim -/- MEFs (figure 5.3A). These proteins are 
located immediately downstream mTORC1 and p70S6K is directly phosphorylated by it. 
Therefore, these proteins are widely used to check mTORC1 activation. These results 
suggest that the activation of mTORC1 is dysregulated in the absence of vimentin, since 
there is less phosphorylation of p70S6K and S6 in Vim -/- MEFs after stimulation. Further, 
there was no significant difference in insulin receptor expression (figure 5.3B), excluding 
differences related to the number of receptors in the cells. Taken together, these data point 
to an interaction between vimentin and upstream mTORC1 regulators. To further investigate 
this, Co-IP studies were conducted to evaluate protein interactions.  
5.3 Vimentin interacts with the Akt/mTOR pathway after stimulation  
Akt must be phosphorylated twice for full activation, once by PDK1 and a second one by 
mTORC2. Since mTORC1 activity was lower in Vim -/- MEFs, one explanation could be 
that mTORC2 was not phosphorylating Akt preventing it from being fully active. Therefore, 
we decided to investigate whether mTORC2 interacted with vimentin. To do so, HDF cells 
were starved with serum free medium the day before the co-IP. Then, they were treated either 
with FCS or insulin for 10 minutes and cells with no treatment were used as control. We 
performed co-IP of RICTOR, a subunit that is specific for mTORC2, which allowed us to 
evaluate the interactions with other proteins. Then SDS-PAGE and western blotting was 
performed with RICTOR antibody followed by reblotting with vimentin. Indeed, an  
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interaction between vimentin and RICTOR was seen upon stimulation of the pathway (figure 
5.4A). This suggests that vimentin might enhance mTORC1 activation, possibly by 
promoting further activation of Akt. Phosphorylation of Akt upon activation of the pathway 
leads to phosphorylation of the TSC complex, releasing and activating mTORC1. Since 
mTORC1 activation was previously shown to be lower in Vim -/- MEFs, we also checked 
interactions between vimentin and the TSC complex by co-IP. Our preliminary data suggests 
that vimentin interacts with TSC2 after stimulation (figure 5.4B), as a vimentin band is seen 
upon insulin or FCS stimulation upon reblotting the TSC nitrocellulose membrane for 
vimentin. In addition, the interaction between vimentin and TSC in the serum starved 
condition of calyculin A treatment suggests that this interaction occurs upon 
phosphorylation, since calyculin A is a phosphatase inhibitor, so the proteins will be in their 
phosphorylated state. Taken together, these data point to an- interaction between vimentin 
and both mTORC2 and TSC2 that could be in a phosphorylation-dependent event. 
Therefore, we then decided to do mass spectrometry to see which sites were phosphorylated 
in each of the treatments. To do so, we performed co-IP of RICTOR as done before, using 
the same conditions, we ran a SDS-PAGE gel and isolated the vimentin band after silver-
Figure 5.3 mTORC1 activation is lower in Vim -/- MEFs. a. Phosphorylation of p70S6K and S6, the proteins 
immediately downstream mTORC1, is lower in Vim -/- MEFs, indicating that the mTORC1 activation is also 
reduced. The cells were starved with serum free medium (SFM) the day before the assay. Then, they were 
treated either with 5 % fetal calf serum (FCS) or 10 nM of insulin for 10 minutes and cells with no treatment 
were used as control, followed by SDS-PAGE and western blotting. b. No difference was seen in insulin 
receptor expression, excluding changes due to the number of receptors available. HSC70 was used as loading 
control. Three independent trials were conducted for this experiment. 
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staining. We digested the samples, separated them by liquid chromatography (LC) and 
performed a data dependent run using a ESI-hybrid-quadrupole-orbitrap mass spectrometer. 
The results are presented in table 5.1 where phosphorylated sites are green and non-
phosphorylated ones are red. The vimentin phosphorylated sites upon insulin or FCS 
treatment that are not phosphorylated in SFM cells, such as Y150, S278 and Y383 are good 
candidates for the possible phosphorylation-dependent interaction between vimentin and 
RICTOR seen with the co-IP results. 
 
 
 
 
Figure 5.4 Vimentin interacts with the Akt/mTOR pathway after stimulation. a. Representative of three 
independent experiments of co-immunoprecipitation of RICTOR, one of the specific subunits of mTORC2. 
Vimentin interacts with RICTOR upon stimulation with either insulin or fetal calf serum (FCS) suggesting that 
vimentin contributes to the complete activation of Akt, promoting cell growth. b. The interaction seen after 
stimulation suggests that vimentin could be enhancing protein synthesis by sequestering the TSC2 inhibitory 
complex. In addition, the interaction in the serum starved condition of calyculin A treatment suggests that this 
interaction occurs upon phosphorylation. HDF cells were starved with serum free medium the day before the 
co-IP. Then, they were treated either with 5 % FCS or 100 nM of insulin for 10 minutes and cells with no 
treatment were used as control. For TSC2, an additional 10 minute treatment with calyculin A was done to the 
cells and cells without this treatment were used as control. The co-IP was performed with magnetic beads, 
using IgG as a negative control (IgG) The co-IP was followed by SDS-PAGE and western blotting. 
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  S5 S22 S29 S39 S56 S83 T101 Y150 T165 T202 S226 S214 Y276 S278 S299 S316 S325 T336 Y358 Y383 S412 T426 S430 T458 S459 
SFM                                                   
INS                                                   
FCS                                                   
Table 5.1 Summary of the results obtained from the co-IP of RICTOR with mass spectrometry in a data dependent run. The first column indicates the treated samples and 
the first row the phosphorylation sites. The colour code indicates if the site was found to be phosphorylated with high confidence (green) or not phosphorylated at all (red). 
After the treatment, co-IP of RICTOR was performed, followed by SDS-PAGE. The band corresponding to vimentin was cut and digested for each sample. The samples 
were separated by LC and they were run in a ESI-hybrid-quadrupole-orbitrap mass spectrometer. Only one experimental replicate was performed for this experiment. 
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6 Discussion 
The existing knowledge on the roles of vimentin in the cell is much greater than when 
vimentin was seen only as a cytoskeletal protein. Today, we understand that this protein 
promotes key processes in the cell, such as proliferation, migration and invasion. This study 
began by identifying the difference in cell size and volume between WT and vim -/- MEFs, 
as well as protein content. These results showed that vim -/- MEFs are not only smaller, with 
lower volume, but have also lower protein amount. Therefore, the differences in size are not 
because of the lack of a cytoskeletal protein but due to overall lower protein mass in vim -/- 
MEFs. Cell size changes depending on which cell cycle phase the cells are. So, we performed 
a 24 hour treatment with thymidine, which allowed us to exclude size differences related to 
cell cycle because this compound synchronizes the cells in G1/S phase (114,115). Then the 
rescuing experiment showed an increase in cell volume after vimentin transfection into vim 
-/- MEFs, suggesting that it is the lack of vimentin that causes the smaller phenotype. 
However, this experiment lacked an empty vector control because we didn’t have the right 
one, but it will be included in the future. Also, protein content and protein synthesis 
experiments should be performed with the transfected cells to complement the results, along 
with SDS-PAGE and western blotting of the proteins of the Akt/mTOR pathway. The lower 
relative level of protein synthesis allowed us to link the size differences with the Akt/mTOR 
pathway. In addition, these results are supported by previous unpublished results in lab that 
showed that after starvation for 36 hours, WT MEFs increase their size after stimulation with 
insulin, unlike vim -/- MEFs, demonstrating very clearly a problem in insulin dependent 
signalling. This phenotype described here agrees with the mice data that demonstrated the 
lower body weight, organ size and smaller adipocytes in vim -/- mice. We had several other 
tissue sections, including smooth muscle, kidney and liver but we were not able to 
successfully study the cell size difference because unlike adipose tissue, these tissues are 
very dense and complex, so it is very challenging to measure, we would need higher 
resolution. Our lab has skin sections where there is also a difference in smooth muscle, and 
Eco-MRI results show that the overall fat and muscle tissue is lower in vim -/- mice. If it 
was possible to successfully section skeletal muscle, one would expect a difference, as it is 
a tissue that responds to insulin, but that is challenging to do because the tissue would lose 
its stretched shape, so the analysis would not be as accurate. The difference in organ size 
could be due to less collagen deposition as well because our lab has previously published 
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that vim -/- MEFs produce less collagen when compared to WT MEFs (36). Nevertheless, 
we plan to perform the cell volume analysis on primary cells isolated from these tissues, 
which would be a better way to compare the results.  
In general, the results summarized so far are in agreement with what has been described 
in the literature about mutations in the Akt/mTOR pathway (103–108). Indeed, we observed 
less mTORC1 activation in vim -/- MEFs after stimulation, as well as lower protein 
synthesis, suggesting a dysregulation in the Akt/mTOR pathway due to the absence of 
vimentin. This is one of the major pathways in the cell; it not only leads to proteins synthesis 
but its members also control proliferation, autophagy, glucose uptake, lipogenesis, motility 
and many other processes (77,92–94). Furthermore, vimentin has already been linked to 
some of these processes, namely, proliferation, autophagy and motility (25,36,94). 
Therefore, here we provide a novel role for vimentin, regulation of cell growth. It would be 
interesting to evaluate the expression and activation of more proteins in the pathway to fully 
understand this mechanism. The co-IP of RICTOR showed an interaction with vimentin. 
RICTOR is part of mTORC2, a complex that can phosphorylate and fully activate Akt. It 
was recently published that mTORC2 can activate the insulin receptor itself (116). It was 
demonstrated that mTORC2 has tyrosine kinase activity and it contributes to activation of 
the insulin receptor, suggesting that instead of the known autophosphorylation of the RTK, 
it would be a combined effort of autophosphorylation and phosphorylation by mTORC2. 
Also, Akt was demonstrated to be able to phosphorylate mTORC2 and promote its activation 
(117). These two feedbacks contradict the known inhibition of the insulin receptor by 
mTORC1 (118,119). However, studies have shown that muscle specific knockout of 
RICTOR does not abolish Akt T308 or S473 phosphorylation (120), which then means that 
mTORC2 is not required for full activation of Akt. On the other hand, another study has 
shown that knockout of RICTOR affects negatively on both Akt phosphorylation sites (121) 
and a recent study has that demonstrated that mTORC2 inhibition leads to suppression in 
Akt T308 phosphorylation (122). Contradictory results by another group state that there is 
an increase of Akt T308 phosphorylation in RICTOR -/- mice (123). These discrepancies 
might be because of the existence of compensatory mechanisms or the use of different 
models for the studies. Nevertheless, here we provide a new step in signalling with our Co-
IP results: vimentin interacts with mTORC2 and regulates cell growth. This is in agreement 
with the previous studies that showed that mTORC2 contributes to the full activation of the 
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Akt/mTOR pathway (116,117,121,122). It was previously published that Akt 
phosphorylates vimentin leading to cell motility (51). This Akt-mediated phosphorylation 
could be one explanation for cell growth as well, but by controlling different downstream 
proteins. Upon insulin receptor activation, Akt phosphorylates mTORC2, TSC and vimentin 
causing them to interact and contribute to the full activation of Akt (figure 6.1.). Supporting 
this claim, there is a study showing that the TSC inhibitory complex is required for proper 
activation of mTORC2 and that these two complexes physically interact (124). Although, 
for this claim, more studies of interactions and kinase activity need to be conducted. Our 
preliminary data of the co-IP of TSC2 suggested an interaction between vimentin and TSC2 
after stimulation, possibly in a phosphorylation dependent manner. However, to support this 
claim, kinase inhibitors should be used. Our mass spectrometry data provided us with a series 
of candidates of vimentin phosphosites that could be involved in the interaction between 
vimentin and RICTOR. The phosphorylated sites after insulin and FCS stimulation that are 
not phosphorylated in the serum starved condition and vice versa, such as S278, Y150 and 
Y383 need to be further studied and validated. First, because the mass spectrometry data 
presented is the result of one trial only and second, this phosphosites need to be validated 
either by using phosphomutants or by heavy peptides in mass spectrometry, run along with 
the samples.  
Figure 6.1 Overview of the proposed model. Upon activation of the pathway, Akt phosphorylates vimentin, 
TSC and mTORC2, causing them to interact to fully activate Akt and lead to protein synthesis. 
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Cell growth is an essential step for cell proliferation and full body homeostasis. The 
Akt/mTOR pathway is a key process in the cell and comprises a group of proteins that can 
provide all sorts of cues related to cell survival by interacting with different proteins. As an 
example, Akt provides for proliferation and growth, but also in glucose uptake and for lipid 
metabolism (77,93). mTORC2 has been shown to be essential for skeletal growth and bone 
formation in mice (125) as well as required for lipogenesis and hepatic glucose metabolism 
(126). Further, it has been shown to sustain thermogenesis via Akt-induced glucose uptake 
and glycolysis in brown adipose tissue (127), which is an anti-obesity mechanism. In fact, 
mice lacking p70S6K also show a lean phenotype and are protected against diet induced 
obesity (128). In addition, diet induced obese mice show higher activity of mTORC1 (129). 
Similarly, prolonged inhibition of mTORC1 with rapamycin in mice improved body 
composition, metabolism and lipid profile (130). Also, in both cases, p70S6K and mTORC1 
downregulation increases lifespan in mice, due to a better metabolism (131). In agreement, 
our vim -/- mice have smaller adipocytes and are much leaner than WT. The lack of vimentin 
causes lower activity of the Akt/mTOR pathway and reduces the likelihood of the mice to 
develop diet induced obesity, therefore these models could be used to understand how to 
overcome this condition. 
Several studies have shown that genes coding for proteins of the Akt/mTOR pathway can 
be amplified or overexpressed in cancer. Further, the proteins of the Akt/mTOR pathway 
can also be hyperactivated (reviewed in (132)). EMT is a key step in metastasis because it 
allows epithelial cells to acquire mesenchymal features, increasing their motility (reviewed 
in (133)). Studies have showed that the activation of the Akt/mTOR pathway is required for 
EMT (134–137). In NMuMG cells, the activation of the transforming growth factor β 
(TGFβ) induced PI3K/Akt (137) activation as well as mTORC2, which activation was 
shown to be required for EMT (135). The authors also referred that the activation of the 
TGFβ pathway was accompanied by an increase in cell size and protein content (134). 
Further, using rapamycin, an inhibitor of mTORC1, impaired the invasive behaviour of the 
cells (134). Studies with a different cell line showed less collagen deposition upon 
knockdown of RICTOR (136). Taken together, these studies highlight an interaction 
between EMT and the Akt/mTOR pathway in cancer. Vimentin has already been linked to 
EMT and collagen deposition (35,36) and it was reported to be an EMT marker. Therefore, 
an increase in cell motility is expected when cancer cells start expressing vimentin and 
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undergoing EMT. The present work provides a link between vimentin and Akt/mTOR 
signalling, showing that vimentin promotes protein synthesis and cell growth by interacting 
with members of the Akt/mTOR pathway. Cell growth is also seen upon EMT activation by 
TGFβ signalling. Therefore, vimentin could be the scaffold protein bringing these pathways 
together and contribute to EMT by integrating these two complex signalling pathways.  
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7 Concluding remarks and future perspectives 
The knowledge related to vimentin and its roles in the cell has evolved a great deal in the 
past years. Our laboratory showed very recently that vimentin is involved in cell proliferation 
and the present work shows that vimentin plays a role in cell growth regulation in MEFs by 
interacting with the Akt/mTOR pathway. This work first showed that Vim -/- MEFs have 
lower volume and protein amount, as well as lower protein synthesis, when compared to WT 
MEFs and we demonstrated that the WT phenotype could be restored by transfecting 
vimentin plasmid into Vim -/- MFEs. Also, we showed that the activation of mTORC1 was 
attenuated in Vim -/- MEFs, upon insulin or serum stimulation. With co-IPs, we showed an 
interaction between vimentin and mTORC2. By mass spectrometry we discovered several 
candidates for this interaction, which need to be further studied. In addition, an interaction 
between vimentin and TSC that seems to be in a phosphorylation dependent manner was 
also demonstrated. Therefore, combining these results with what was described in the 
literature, we postulated that upon activation of Akt, it would phosphorylate TSC, vimentin 
and mTORC2, leading to the formation of a complex that would contribute to the full 
activation of Akt and promote protein synthesis. Cell growth, a process highly dependent on 
the synthesis of macromolecules such as proteins, is an essential step for proliferation, 
development and full body homeostasis. Full activation of Akt, that seems to be deficient in 
vim -/- MEFs, is a crucial step for not only this pathway but also other cues that rely on Akt, 
such as glucose uptake, lipid metabolism and autophagy. Therefore, since vim -/- are leaner 
and have smaller adipocytes, the lack of vimentin reduces the likelihood of these mice 
developing diet induced obesity and that this model could be used to understand how to 
overcome this condition. For the future, we plan to isolate primary cells from different mouse 
tissues to perform the same cell volume analysis as we have shown here. We also want to 
continue the mass spectrometry experiments and proceed with the validation of these results 
using phosphomutants. In addition, we will try to fully understand the differences in the 
Akt/mTOR pathway in MEFs by checking the expression and activation of other proteins 
and validate the preliminary data of the co-IP of TSC2.  We will also perform protein kinase 
activity assays to show the activity of the proteins involved in the interactions that we saw.  
Stimulated emission depletion microscopy (STED), a high-resolution technique will be used 
to show the interactions of vimentin with the proteins of the Akt/mTOR pathway and 
complement the results. 
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